Keensight Capital-backed Symeres to acquire Exemplify BioPharma.

Keensight Capital-backed Symeres, a global drug discovery company, agreed to acquire Exemplify BioPharma, a pharmaceutical company. FInancial terms were not disclosed. “We are proud to see Exemplify BioPharma’s scientific expertise and strategic location in North America recognized and become part of the Symeres family. Symeres is a trusted partner that shares our values and business philosophy of strong customer focus. Exemplify BioPharma’s recent move to our new and larger state-of-the-art facility, and the combination with a global business like Symeres, will allow us to better serve our clients under one roof. We look forward to accelerating our growth together,” Yadan Chen, Exemplify BioPharma CEO.